Wenjie Zhang1, Ning Mao2, Yongsheng Wang2, Haizhu Xie2, Shaofeng Duan3, Xuexi Zhang3, Bin Wang4. 1. School of Clinical Medicine, Binzhou Medical University, Yantai, Shandong, 264000, PR China. 2. Department of Radiology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, 264000, PR China. 3. GE Healthcare, China, Shanghai, 200000, PR China. 4. School of Clinical Medicine, Binzhou Medical University, Yantai, Shandong, 264000, PR China. Electronic address: binwang001@aliyun.com.
Abstract
PURPOSE: To establish and validate a radiomics nomogram for predicting bone metastasis (BM) in patients with newly diagnosed prostate cancer (PCa). METHOD: One-hundred and sixteen patients (training cohort: n = 81; validation cohort: n = 35) who underwent prostate MR imaging and confirmed by pathology with newly diagnosed PCa from January 2014 to January 2019 were enrolled. Radiomic features were extracted from diffusion-weighted, axial T2-weighted fat suppression, and dynamic contrast-enhanced T1-weighted MRI of each patient. Dimension reduction, feature selection, and radiomics feature construction were performed using the least absolute shrinkage and selection operator (LASSO) regression. Combined with independent clinical risk factors, a multivariate logistic regression model was used to establish a radiomics nomogram. Nomogram calibration and discrimination were evaluated in training cohort and verified in the validation cohort. Finally, the clinical usefulness of the nomogram was estimated through decision curve analysis (DCA). RESULTS: Radiomics signature consisting of 12 selected features was significantly correlated with bone status (P < 0.001 for both training and validation sets). The radiomics nomogram combined a radiomics signature from multiparametric MR images with independent clinic risk factors. The model showed good discrimination and calibration in the training cohort (AUC 0.93, 95% CI, 0.86 to 0.99) and the validation cohort (AUC 0.92, 95% CI, 0.84 to 0.99). DCA also demonstrated the clinical use of the radiomics model. CONCLUSION: The radiomics nomogram, which incorporates the multiparametric MRI-based radiomics signature and clinical risk factors, can be conveniently used to promote individualized prediction of BM in patients with newly diagnosed PCa.
PURPOSE: To establish and validate a radiomics nomogram for predicting bone metastasis (BM) in patients with newly diagnosed prostate cancer (PCa). METHOD: One-hundred and sixteen patients (training cohort: n = 81; validation cohort: n = 35) who underwent prostate MR imaging and confirmed by pathology with newly diagnosed PCa from January 2014 to January 2019 were enrolled. Radiomic features were extracted from diffusion-weighted, axial T2-weighted fat suppression, and dynamic contrast-enhanced T1-weighted MRI of each patient. Dimension reduction, feature selection, and radiomics feature construction were performed using the least absolute shrinkage and selection operator (LASSO) regression. Combined with independent clinical risk factors, a multivariate logistic regression model was used to establish a radiomics nomogram. Nomogram calibration and discrimination were evaluated in training cohort and verified in the validation cohort. Finally, the clinical usefulness of the nomogram was estimated through decision curve analysis (DCA). RESULTS: Radiomics signature consisting of 12 selected features was significantly correlated with bone status (P < 0.001 for both training and validation sets). The radiomics nomogram combined a radiomics signature from multiparametric MR images with independent clinic risk factors. The model showed good discrimination and calibration in the training cohort (AUC 0.93, 95% CI, 0.86 to 0.99) and the validation cohort (AUC 0.92, 95% CI, 0.84 to 0.99). DCA also demonstrated the clinical use of the radiomics model. CONCLUSION: The radiomics nomogram, which incorporates the multiparametric MRI-based radiomics signature and clinical risk factors, can be conveniently used to promote individualized prediction of BM in patients with newly diagnosed PCa.
Authors: Eliodoro Faiella; Domiziana Santucci; Alessandro Calabrese; Fabrizio Russo; Gianluca Vadalà; Bruno Beomonte Zobel; Paolo Soda; Giulio Iannello; Carlo de Felice; Vincenzo Denaro Journal: Int J Environ Res Public Health Date: 2022-02-08 Impact factor: 3.390
Authors: Marcin Miszczyk; Justyna Rembak-Szynkiewicz; Łukasz Magrowski; Konrad Stawiski; Agnieszka Namysł-Kaletka; Aleksandra Napieralska; Małgorzata Kraszkiewicz; Grzegorz Woźniak; Małgorzata Stąpór-Fudzińska; Grzegorz Głowacki; Benjamin Pradere; Ekaterina Laukhtina; Paweł Rajwa; Wojciech Majewski Journal: Cancers (Basel) Date: 2022-03-23 Impact factor: 6.639
Authors: Matteo Ferro; Ottavio de Cobelli; Gennaro Musi; Francesco Del Giudice; Giuseppe Carrieri; Gian Maria Busetto; Ugo Giovanni Falagario; Alessandro Sciarra; Martina Maggi; Felice Crocetto; Biagio Barone; Vincenzo Francesco Caputo; Michele Marchioni; Giuseppe Lucarelli; Ciro Imbimbo; Francesco Alessandro Mistretta; Stefano Luzzago; Mihai Dorin Vartolomei; Luigi Cormio; Riccardo Autorino; Octavian Sabin Tătaru Journal: Ther Adv Urol Date: 2022-07-04
Authors: Simon K B Spohn; Alisa S Bettermann; Fabian Bamberg; Matthias Benndorf; Michael Mix; Nils H Nicolay; Tobias Fechter; Tobias Hölscher; Radu Grosu; Arturo Chiti; Anca L Grosu; Constantinos Zamboglou Journal: Theranostics Date: 2021-07-06 Impact factor: 11.556